SPPI
Spectrum Pharmaceuticals IncSPPI
SPPI
Delisted
SPPI was delisted on the 31st of July, 2023.
About: Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.
Employees: 86
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Spectrum Pharmaceuticals, Inc. Litigation
SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the proposed Settlement in the Spectrum Pharmaceuticals, Inc. Litigation: UNITED STATES DISTRICT COURT DISTRICT OF NEVADA JOSE CHUNG LUO, Individually and on Behalf of All Others Similarly Situated, Civil Action No. 2:21-cv-01612-CDS-BNW CLASS ACTION Plaintiff, vs. SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION SPECTRUM PHARAMCEUTICALS, INC., et al.
Neutral
GlobeNewsWire
3 weeks ago
Pneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum Antiviral
St Andrews, UK – 2 July 2025 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), announces the publication of its Phase II Proof of Concept, Controlled Human Infection Model (CHIM) study investigating the efficacy and safety of Neumifil in the peer-reviewed journal Infectious Diseases and Therapy.
Neutral
PRNewsWire
3 weeks ago
IDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial
GUANGZHOU, China , July 2, 2025 /PRNewswire/ -- Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the Independent Data Monitoring Committee (IDMC) has recommended early study termination for the pivotal Phase II/III trial of BAT4406F in neuromyelitis optica spectrum disorder (NMOSD) based on positive interim analysis results. Following this recommendation, Bio-Thera has decided to close patient enrollment ahead of schedule.
Neutral
Accesswire
3 weeks ago
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with advancing its lead candidate NV-387 into Phase II clinical drug development.
Neutral
GlobeNewsWire
1 month ago
Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release
Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax' broad-spectrum influenza A vaccine candidate. Osivax expects to announce final results from the booster trial in H2 2025.
Neutral
Accesswire
2 months ago
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC).
Neutral
PRNewsWire
6 months ago
Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders
GUANGZHOU, China , Jan. 14, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd. today announced the publication of the Phase I clinical study results for BAT4406F, an ADCC-enhanced fully humanized anti-CD20 monoclonal antibody in Chinese patients with neuromyelitis optica spectrum disorders (NMOSD) in the journal CNS Neuroscience & Therapeutics.
Neutral
GlobeNewsWire
9 months ago
Qylur Awarded SBIR Phase II Contract for Tactical AI Spectrum Classifier Systems (TASCS)
Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority
Neutral
GlobeNewsWire
9 months ago
Qylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)
Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority Qylur's SNIM® AI and Autonomous Systems capabilities to address key challenge for Agile Spectrum Superiority
Positive
Proactive Investors
11 months ago
NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387
NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which has shown promise in treating various viral infections including RSV, COVID-19, and Influenza in animal studies, could revolutionize the treatment of respiratory viruses, according to the company.
Charts implemented using Lightweight Charts™